Key Points
- CEO Christian Behrenbruch bought 34,500 shares on April 28 at an average of $14.48 ($499,560) and 33,435 shares on April 29 at $14.87 ($497,178), bringing his direct stake to 20,709,500 shares (≈$299.9M), a roughly 0.17% increase.
- Telix missed earnings and revenue estimates for the quarter, reporting ($0.01) EPS versus a $0.05 consensus and $206.72M in revenue versus $421.50M expected.
- Analysts hold a consensus "Moderate Buy" rating with an average target price of $21.13; the stock's 12‑month range is $6.28 to $18.49.
Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) CEO Christian Behrenbruch purchased 33,435 shares of the stock in a transaction that occurred on Wednesday, April 29th. The stock was acquired at an average cost of $14.87 per share, with a total value of $497,178.45. Following the acquisition, the chief executive officer owned 20,742,935 shares in the company, valued at $308,447,443.45. The trade was a 0.16% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.
Christian Behrenbruch also recently made the following trade(s):
- On Tuesday, April 28th, Christian Behrenbruch purchased 34,500 shares of Telix Pharmaceuticals stock. The stock was acquired at an average cost of $14.48 per share, with a total value of $499,560.00.
Telix Pharmaceuticals Trading Up 0.6%
Shares of NASDAQ:TLX opened at $11.11 on Thursday. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Telix Pharmaceuticals Limited has a 12 month low of $6.28 and a 12 month high of $18.49. The company has a 50-day moving average price of $9.10 and a 200 day moving average price of $8.77.
Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last announced its quarterly earnings results on Friday, February 20th. The company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million for the quarter, compared to analysts' expectations of $421.50 million. As a group, research analysts expect that Telix Pharmaceuticals Limited will post 0.09 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on TLX shares. Royal Bank Of Canada raised shares of Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Monday, January 19th. HC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Monday, April 13th. Citigroup increased their price objective on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a "buy" rating in a research report on Tuesday, February 24th. Wall Street Zen raised shares of Telix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, April 11th. Finally, Weiss Ratings reissued a "sell (d)" rating on shares of Telix Pharmaceuticals in a research report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $21.13.
Check Out Our Latest Stock Report on TLX
Hedge Funds Weigh In On Telix Pharmaceuticals
Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers increased its position in shares of Telix Pharmaceuticals by 117.3% during the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock worth $25,000 after acquiring an additional 1,392 shares during the period. XTX Topco Ltd purchased a new position in shares of Telix Pharmaceuticals during the fourth quarter worth approximately $89,000. OLD Mission Capital LLC purchased a new position in shares of Telix Pharmaceuticals during the fourth quarter worth approximately $111,000. Vident Advisory LLC purchased a new position in shares of Telix Pharmaceuticals during the fourth quarter worth approximately $204,000. Finally, IHT Wealth Management LLC purchased a new position in shares of Telix Pharmaceuticals during the second quarter worth approximately $213,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.
The company’s pipeline spans both imaging and therapeutic candidates.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
